ReviewThe British journal of radiology2021
PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
Review in The British journal of radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Prognostic Impact of Extranodal Organ Burden in Classical Hodgkin Lymphoma with Extranodal Involvement: A Retrospective Cohort Analysis.Journal of clinical medicine · 2026Article
- ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma.Blood neoplasia · 2026Article
- Article
- Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT.Blood research · 2022Review
- Lymphoma: New Diagnosis and Current Treatment Strategies.Journal of clinical medicine · 2022Article
- Metabolic response to radiation therapy in cancer.Molecular carcinogenesis · 2022Review
- Lymphoma: advances in imaging and radiotherapy - introductory editorial.The British journal of radiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FDG-PET scanning has a central role in lymphoma staging and response assessment. There is a growing body of evidence that PET response assessment during and after initial systemic therapy can provide useful prognostic information, and PET response has an evolving role in guiding patient care. This review provides a perspective on the role of PET response assessment for individualised management of patients with the most common aggressive lymphomas, Hodgkin lymphoma and diffuse large B-cell lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.